This study was an open-label, adaptive phase 2/3 trial assessing the effectiveness of T-DM1 against a taxane (docetaxel or paclitaxel) in individuals with HER2-positive advanced gastric cancer who had received prior treatment. This evidence concerns the gene ERBB2 and gastric cancer.